The Latest Breaking News from TLRY

The cannabis industry is undergoing a turbulent time due to legalization troubles and its struggles to realize gains. Amid this, would it be wise to invest in Tilray Brands (TLRY) and Canopy Growth (CGC) this year? Keep reading….

Tilray Brands (TLRY) posted record net revenue in its most recent quarter. So, is this the right entry point in the stock? Let’s analyze some of its key financial metrics to gauge its prospects.

The pharmaceutical industry’s robust outlook is driven by high healthcare spending globally, consistent R&D efforts, and the rapid adoption of advanced digital technologies. So, let’s analyze if investors should adopt a bullish or bearish stance on pharma stocks such as Tilray Brands (TLRY), CytomX Therapeutics (CTMX), and Wave Life Sciences…

Tilray Brands (TLRY) holds the leadership position in the cannabis market of Canada. Additionally, it is making forays into the beverages market to spur its growth. However, the federal legalization of cannabis in the United States is still some time away. With the company scheduled to release its earnings on…

The pharmaceutical sector performs relatively well during economic uncertainties due to inelastic demand for its products and services. While prominent players Tilray Brands (TLRY) and Novo Nordisk (NVO) should benefit, which stock is the better buy now? Read more to find out.

Canadian cannabis leader Tilray Brands (TLRY) is bolstering its portfolio through expansions and partnerships. However, the company’s recent $150 million offering of senior notes put pressure on its stock price. Would it be wise to buy the stock now? Let’s look at its financial metrics to answer that….

Despite legalization gaining traction, the cannabis industry's prospects for the year ahead remain grim due to several economic and industry-wide headwinds. As a result, it seems wise to avoid sinking cannabis stocks Curaleaf Holdings (CURLF), Tilray Brands (TLRY), and Verano Holdings (VRNOF). Read more….

The cannabis industry has been facing several economic and regulatory challenges. Demand has also slowed amid a glut in supply. With the Fed unlikely to stop interest rate hikes, the economy could enter a recession this year. Amid this backdrop, it could be wise to avoid fundamentally weak cannabis stocks…

Despite significant growth in recent years driven by increased legalization, the cannabis industry took a hit last year amid economic and industry-wide headwinds, including stubborn supply gluts. Furthermore, the industry will likely remain under pressure this year due to economic challenges. Hence, it could be wise to avoid fundamentally weak…

Despite the banking industry crisis, the Fed is expected to launch another rate hike next week as it remains committed to bringing inflation down. Therefore, fundamentally weak stocks Snap (SNAP), Peloton Interactive (PTON), and Tilray Brands (TLRY) might be best avoided as they might plunge further. Keep reading.

Following remarkable growth in recent years, the cannabis industry faced various legal and economic challenges, including overproduction amid high inflation, high taxes, and increased material costs impacting overall sales in 2022. The industry will likely remain under pressure amid concerns over rising inflation and a potential recession. Hence, it could…